| 2015-04-27 |
1 |
|
Patent No. Issue Date Patent Expiry
6,150,383 (the…its patent information that the two patents—United States Patent
Nos. 5,965,584 (the “’584 Patent”) and…manufacturer’s patents and patent information for accuracy or
trustworthiness. In listing patents and patent information…the ’777 Patent, the ’584 Patent, and the ’404 Patent, Takeda
submitted eight other patents to the FDA…the ’584 Patent and the ’404 Patent as drug
product patents claiming ACTOS only if the patents in fact |
External link to document |
| 2019-10-08 |
131 |
Memorandum & Opinion |
two other patents-U.S. Patent Nos. 5,965,584 (the "'584 patent") and 6,329,404 (the "… several patents related to its diabetes medicines.
The first of those patents, U.S. Patent. No. 4,687,777…hereinafter, "the Patents") as both drug product patents and method-of-use patents-and
improperly … Normally, inventors obtain
patents for their brand-name drugs. Patents that protect a drug may include…such patents
must be submitted with an NDA is at the heart of this case.
For each patent that |
External link to document |
| 2016-01-06 |
54 |
|
Patent No. Issue Date Patent Expiry
6,150,383 (the…listed three additional patents – the ’042 Patent, the ’043 Patent, and the
’090 Patent – as applicable method-of-use…Takeda asserted in its patent information that the two patents – United States Patent Nos.
5,965,584 (the…misleading patent information regarding the ’584 Met Combo Patent and ’404 Insulin Combo
Patent for ACTOS…
drug substance patent – U.S. Patent No. 4,687,777 (the “’777 ACTOS Compound Patent”) –
expired on January |
External link to document |
| 2016-01-07 |
55 |
|
Patent No. Issue Date Patent Expiry
6,150,383 (the…listed three additional patents – the ’042 Patent, the ’043 Patent, and the
’090 Patent – as applicable method-of-use…Takeda asserted in its patent information that the two patents – United States Patent Nos.
5,965,584 (the…misleading patent information regarding the ’584 Met Combo Patent and ’404 Insulin Combo
Patent for ACTOS…
drug substance patent – U.S. Patent No. 4,687,777 (the “’777 ACTOS Compound Patent”) –
expired on January |
External link to document |
| 2016-01-27 |
62 |
|
medications: U.S. Patent Nos. 5,965,584 (“’584 patent”) and 6,329,404
(“’404 patent”), both of which …U.S. Patent No. 4,687,777
(“’777 patent”), which expired in January 2011. Id. ¶ 158. Two patents claim…traditional patent settlement, Teva (the alleged
patent infringer) agreed to pay Takeda (the patent holder… the underlying patent infringement
cases, or (2) the supposed weakness of the patent claims would have…relating
to the ACTOS and ACTOplus met patent litigations and patent settlements are no different from
those |
External link to document |
| 2016-01-27 |
65 |
|
’584 patent at 18:19-21, 18:65-67 (claims 4 and 10).
Takeda received U.S. Patent No. 6,329,404, which…pioglitazone patents, including the ’777, ’584, and ’404
patents, as well as the method-of-use patents, for … and ’404 patents only as “method-
of-use” patents for ACTOS and never as “product” patents, as shown…Takeda had not
described the patents as “product” patents in its patent submission letters to the FDA…to list a patent. For
each patent, pioneer drug companies are required to submit the patent if and only |
External link to document |
| 2016-03-21 |
75 |
|
December 2001, the PTO issued U.S. Patent No. 6,329,404.53 The ’404 patent also
has two types of claims, …in the patent that covered the drug: a “drug” (drug
substance) patent, a “drug product” patent, or a …not involve a patented method of use with respect to the method of use patent or patent
claim.”).
…Takeda's patent
declarations for the ’584 and ’404 patents each stated that the patents claimed both…sponsor’s patent declaration describing relevant patent claims in Orange
Book-listed patents.”113 The |
External link to document |
